6/14
08:10 am
vyne
VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.
Medium
Report
VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.
6/13
09:08 am
vyne
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202 [Yahoo! Finance]
Medium
Report
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202 [Yahoo! Finance]
6/13
09:02 am
vyne
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
Low
Report
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
6/5
12:11 pm
vyne
VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.
Neutral
Report
VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.
6/5
08:17 am
vyne
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201 [Yahoo! Finance]
Low
Report
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201 [Yahoo! Finance]
6/5
08:00 am
vyne
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
Low
Report
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
5/9
10:42 am
vyne
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
Low
Report
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
5/9
08:12 am
vyne
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
6/4
04:30 pm
vyne
Form 4 VYNE Therapeutics Inc. For: May 31 Filed by: Domzalski David
Low
Report
Form 4 VYNE Therapeutics Inc. For: May 31 Filed by: Domzalski David
5/9
04:02 pm
vyne
Form 10-Q VYNE Therapeutics Inc. For: Mar 31
Low
Report
Form 10-Q VYNE Therapeutics Inc. For: Mar 31
5/9
08:01 am
vyne
Form 8-K VYNE Therapeutics Inc. For: May 09
Medium
Report
Form 8-K VYNE Therapeutics Inc. For: May 09
4/3
05:08 pm
vyne
Form 4 VYNE Therapeutics Inc. For: Apr 01 Filed by: Zeronda Tyler
Medium
Report
Form 4 VYNE Therapeutics Inc. For: Apr 01 Filed by: Zeronda Tyler
4/3
05:06 pm
vyne
Form 4 VYNE Therapeutics Inc. For: Apr 01 Filed by: Stuart Iain
Medium
Report
Form 4 VYNE Therapeutics Inc. For: Apr 01 Filed by: Stuart Iain
4/3
05:04 pm
vyne
Form 4 VYNE Therapeutics Inc. For: Apr 01 Filed by: Harsch Mutya
Medium
Report
Form 4 VYNE Therapeutics Inc. For: Apr 01 Filed by: Harsch Mutya
4/3
05:03 pm
vyne
Form 4 VYNE Therapeutics Inc. For: Apr 01 Filed by: Domzalski David
Medium
Report
Form 4 VYNE Therapeutics Inc. For: Apr 01 Filed by: Domzalski David
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register